Skip to main content
Springer logoLink to Springer
. 2013 Dec 7;16(1):2153. doi: 10.1007/s11051-013-2153-9

Occupational safety and health criteria for responsible development of nanotechnology

P A Schulte 1,, C L Geraci 1, V Murashov 1, E D Kuempel 1, R D Zumwalde 1, V Castranova 1, M D Hoover 1, L Hodson 1, K F Martinez 1,2
PMCID: PMC3890581  PMID: 24482607

Abstract

Organizations around the world have called for the responsible development of nanotechnology. The goals of this approach are to emphasize the importance of considering and controlling the potential adverse impacts of nanotechnology in order to develop its capabilities and benefits. A primary area of concern is the potential adverse impact on workers, since they are the first people in society who are exposed to the potential hazards of nanotechnology. Occupational safety and health criteria for defining what constitutes responsible development of nanotechnology are needed. This article presents five criterion actions that should be practiced by decision–makers at the business and societal levels—if nanotechnology is to be developed responsibly. These include (1) anticipate, identify, and track potentially hazardous nanomaterials in the workplace; (2) assess workers’ exposures to nanomaterials; (3) assess and communicate hazards and risks to workers; (4) manage occupational safety and health risks; and (5) foster the safe development of nanotechnology and realization of its societal and commercial benefits. All these criteria are necessary for responsible development to occur. Since it is early in the commercialization of nanotechnology, there are still many unknowns and concerns about nanomaterials. Therefore, it is prudent to treat them as potentially hazardous until sufficient toxicology, and exposure data are gathered for nanomaterial-specific hazard and risk assessments. In this emergent period, it is necessary to be clear about the extent of uncertainty and the need for prudent actions.

Keywords: Risk assessment, Ethics, Risk management, Regulation, Toxicology, Environmental and health effects

Introduction

The responsible development of nanotechnology is a goal of many organizations worldwide (e.g. Royal Society and Royal Academy of Engineering 2004; NIOSH 2005; Jacobstein 2006; CEST 2008; Tomellini and Giordani 2008; Luigi 2009; Nanocyl 2009; NNI 2011; Forloni 2012; VCI 2012; BASF 2013; BIAC 2013). Ideally, the concept of responsible development of nanotechnology implies that there are criteria against which to evaluate development. The focus of those criteria is the prevention of harm to people, and the environment. Workers are the first people exposed to the potential hazards of any new technology including nanotechnology, since they are involved in the research, development, manufacture, production, use, recycling, and disposal of nanomaterials or products containing nanomaterials. Workers often have the highest exposure, which may occur early in the development of a technology when hazards and risks are uncertain. If exposure to nanomaterials harms workers, then nanotechnology is not being responsibly developed. For these reasons, occupational safety and health is the cornerstone of responsible nanotechnology development (Maynard and Kuempel 2005; Schulte and Salamanca-Buentello 2007; Seaton et al. 2010). Anticipating and preventing harm to consumers from products containing nanomaterials is also part of responsible development, as is anticipating how nanomaterials might adversely impact the environment.

There is a moral imperative for worker protection which is of paramount importance, i.e., workers have rights to a safe work environment (Gewirth 1986). Thus, safety of work was recognized as a basic human right by the 2008 Seoul Declaration on Safety and Health at Work (ILO 2008). These rights bring commensurate responsibilities for employers and government authorities to protect workers from harm as fully as is reasonably possible. These responsibilities have been codified in laws and regulations such as the Occupational Safety and Health (OSH) Act, the Mine Safety and Health (MSH) Act, the Toxic Substances Control Act (TSCA) in the United States, and similar legislation and guidance worldwide (e.g., WHO 1994; BAuA 2007; Nanosafe 2008; ISO 2009; Japan NIOSH 2009; Pelley and Saner 2009; Bayer 2010; Murashov et al. 2011; Nakanishi 2011a, b).

Underlying the criteria for responsible development of nanotechnology is the need to be proactive in taking steps to limit exposure of workers, consumers, and the environment to nanomaterials before actual risks are fully understood (Kreider and Halperin 2011). These criteria are not new, but build on basic OSH principles that should be applied to nanotechnology at the early stages in its development. While evidence-based risk assessment and management are the ideals, often action must be taken with less than strong evidence. Moreover, the ultimate component of responsible development is to reduce hazards and risks to the extent feasible and to communicate with, and engage, affected parties (workers) in the management of risks. In this article, the occupational safety and health criteria for responsible development of nanotechnology are defined and their implications are described. These criteria can be considered at the business enterprise and societal levels. Ideally, the criteria would be developed at the societal level (by government agencies, trade, and professional associations, unions, non-governmental organizations (NGOs), insurers, scientists) first and then promoted for use at the business enterprise level (employers, suppliers, business customers). In reality, nanotechnology products were in commerce before criteria for responsible development were in place. That does not mean that there were no applicable societal expectations. The whole history of societal response to hazardous materials provided a framework to initially address the products of nanotechnology. Already in place, as mandated by the OSH Act of 1970 (Public Law 91–596) in the United States, as well as guidance developed by other countries and organizations (e.g., EU Directive 89/336/EEC and Directive 98/21/EC), was the concept that the employer must provide a safe and healthy workplace. Definitions of “safe” and “healthy” for nanomaterials build on experience gained in the 20th century on addressing worker hazards and risks from exposure to fine dusts and powders in various industries such as pigment, pharmaceutical, nuclear, and pesticide manufacturing (Higgins 1917; Dressen et al. 1938; Cook 1945; Sargent and Kirk 1988; Maiello and Hoover 2011). Also, in place were validated risk management practices for controlling fine dusts and powders coming out of the fields of aerosol science, industrial hygiene, exposure assessment, toxicology, and engineering (Hinds 1999).

A body of knowledge developed over the past 100 years shows that small particles can, on an equal mass basis, be more hazardous than larger ones (Driscoll 1996; IOM 2000; Zhang et al. 2000, 2003; Brown et al. 2001; Duffin et al. 2002; Oberdörster et al. 2007; Seaton et al. 2010). Thus, it was known, before, engineered nanomaterials entered commerce that incidental nanoparticles (e.g., welding and diesel fumes) could be carcinogenic when inhaled (Oberdörster and Yu 1990; Heinrich et al. 1995; Antonini 2003); that small aerosol pollutants were linked to respiratory and cardiovascular risks (Dockery et al. 1993; Pope et al. 2002); and that certain “legacy produced” nanomaterials such as ultrafine titanium dioxide, carbon black, and fumed silica were respiratory hazards (Reuzel et al. 1991; Oberdörster et al. 1994; Gardiner et al. 2001; Merget et al. 2002). Clearly too, there also was extensive literature that larger (microscale) inhaled particles are known respiratory hazards (e.g., silica, coal dust) (NIOSH 2002, 2011a). The relationship between particle lung dose and adverse lung effects (e.g., pulmonary inflammation or lung tumors in rats) has been observed to be nonlinear for poorly-soluble low toxicity particles, with no clear particle size threshold (NIOSH 2011b). Nonetheless, for many decision-makers at the business or societal levels, how to define the responsible approach for the safe development of engineered nanomaterials was unclear; and, in some cases, it remains so today, in the second decade of commercialization. This is despite the fact that precautionary guidance has been promulgated by authorities since the mid-2000s (EU-OSHA 2002; Roco and Bainbridge 2003; Hett 2004; HSE 2004; NNI 2004; NIOSH 2005; SCENIHR 2005; ISO 2007; Safe Work Australia 2010a; OSHA 2013).

Criteria for responsible development

Five criterion actions (Table 1) may be considered that demonstrate responsible development from an occupational safety and health perspective. These include: (1) anticipate, identify, and track potentially hazardous nanomaterials in the workplace; (2) assess workers’ exposures to nanomaterials; (3) assess and communicate hazards and risks to workers; 4) manage occupational safety and health risks; and (5) foster the safe development of nanotechnology and the realization of its societal and commercial benefits. These criteria can be assessed at the business enterprise and societal levels. They are based on various influences, including the history of occupational safety and health in the 20th century; the anticipatory work of various researchers and officials (Ashford 1976; Samuels 1986; Colvin 2002; Roco 2003; Aitken et al. 2004; Maynard and Kuempel 2005; Maynard 2006; Murashov and Howard 2008; Tomellini and Giordani 2008; Howard 2011; Roco et al. 2011; Murashov and Howard 2013); the ethical framework described by Schulte and Salamanca-Buentello (2007); and the practices of governmental agencies [e.g., the National Institute for Occupational Safety and Health (NIOSH)], corporations, and labor organizations worldwide conducting research or developing risk management guidance. The criteria also build on the 1983 and 2009 risk assessment paradigms by the U.S. National Research Council (NRC 1983) of the National Academies of Science; the Rio Conference of 1992 (UN 1992); the reports by the National Academy of Engineering (2004) and the Royal Society and Royal Academy of Engineering (2004); the principles of tiered toxicological screening (Oberdörster et al. 2005); and the Nano Risk Framework (2007).

Table 1.

Occupational safety and health criteria that demonstrate responsible development of nanotechnology

Criteria Business enterprise responsibility Societal responsibility
Anticipate, identify, and track potentially hazardous nanomaterials in the workplace

Identify nanomaterials in the workplace

Conduct toxicologic research

Take precautionary (prudent) approaches

Issue anticipatory guidance

Conduct toxicologic research

Issue hazard guidance and control

Assess workers' exposures to nanomaterials Measure exposure Provide guidance on metrics, sampling methods, and analysis
Assess and communicate hazards and risks to workers

Conduct hazard and risk assessments

Communicate hazard and risk information to workers

Train workers in safe handling techniques

Conduct hazard and risk assessments, including quantitative estimates

Communicate risk information to employers, unions, workers, other agencies, and the public

Manage occupational safety and health risks

Manage workplace risks from nanomaterials

 Control exposures

 Monitor workers exposure and health

Include many partners to develop governance strategies

Issue guidance on workplace risk management

 OELs (occupational exposure limits)

 Engineering controls and PPE (personal protective equipment)

 Medical surveillance

Foster the safe development of nanotechnology and the realization of societal and commercial benefits

Protect workers from any harm from nanomaterials

Convey the degree of uncertainty known about risks

Acknowledge hazards

Support precautionary approaches

Document the effectiveness of controls

Convey the degree of certainty about hazards and risks

Conduct research to address uncertainties

Demonstrate the effectiveness of controls

Address relationship between occupational and environmental hazards

Work globally

Support education and scientific literacy

Integration of knowledge from all these related criteria is important, because (Fig. 1; Table 2) actions under one criterion may influence actions under the others (European Commission 2005; Kuempel et al. 2012a; Savolainen 2012). Hazard information generally will drive much of the downstream actions, but each criterion can influence all the others. Responsible development requires integrated action among decision-makers addressing each criterion. At the business level, this may include activities of employers along the supply and value chains, and lifecycle of products. At the societal level, this can include activity of regulators, trade and professional associations, insurers, and NGOs, in endeavors supporting each criterion and all of them taken together.

Fig. 1.

Fig. 1

Interrelation of criteria for responsible development of nanotechnology

Table 2.

Relationship between occupational safety and health criteria for responsible development of nanotechnology

Relationshipa Implications
1.b HI ↔ EA Provides priorities for exposure assessment
2. EA ↔ RA Component factor in risk assessment provides priorities for exposure assessment
3. RA ↔ RM Informs risk management
4. RM ↔ FB Minimizes worker risks and enhances societal acceptance
5. HI ↔ RA Component factor in risk assessment; provides priorities for toxicology study
6. HI ↔ RM Triggers risk management
7. HI ↔ FB Identifying worker hazards useful for identifying consumer and environmental hazards
8. EA ↔ RM Assessing exposures is critical in controlling them
9. EA ↔ FB Identifying risk of exposures to workers provides information needed for effective risk management
10. RA ↔ FB True depiction of risks and risk management decisions to minimize risk enhances societal acceptance

a HI hazard identification (anticipate, identify and track potentially hazardous nanomaterials in the workplace), EA exposure assessment (assess workers exposures to nanomaterial), RA risk assessment (assess and communicate hazards and risks to workers), RM risk management (manage occupational safety and health risks), FB foster benefits (foster the safe development of nanotechnology and the realization of societal and commercial benefits)

bNumber pertains to linkages in Fig. 1

The overarching driver in responsible development of nanotechnology and for each criterion is establishing responsibility for workplace safety and worker exposure. At the business level, the responsibility for a safe and healthy workplace is that of the employer. Early in the commercialization of nanotechnology, many employers indicated that they did not know much about the hazards, risk, exposure, and control of nanomaterials. This uncertainty about the hazards and risks could have resulted in many employers not undertaking the necessary responsibility to protect their workers (Ponce Del Castillo 2013). This uncertainty about risks prompted government agencies to provide guidance on these issues. Workers and their representatives also have responsibilities to advocate for safe and healthy workplaces, to encourage and participate in risk management efforts at the business level, and to advocate for protective guidance at the societal level (CalOSHA 2013; HSE 2013). Society as a whole has the responsibility to support and empower employers, workers, unions, governments, and others in meeting their responsibilities. In addition, the public must be knowledgeable and engaged in deliberations considering new technologies, especially in regards to potential health risks that might be associated with this technology.

Anticipate, identify, and track potentially hazardous nanomaterials in the workplace

Due diligence and legal mandates require employers to be aware of hazards to which their employees could be exposed and all hazards present in facilities that they control (including nanomaterials as well as other chemical or physical hazards). When there is uncertainty about the nature, degree, and extent of hazards of nanomaterials, it is incumbent on employers to know what nanomaterials are in their workplaces, to identify processes where exposures can occur, and to support studies to determine the bioactivity of the nanomaterials. This is not always a simple matter for employers who might unknowingly be using intermediaries or product ingredients containing nanomaterials. Recent data have suggested that important information with regard to nanomaterials is not being included on current Safety Data Sheets (Safe Work Australia 2010b; Eastlake et al. 2012; Lee et al. 2012). In addition, with the advent and rollout of the globally harmonized system (GHS) of classification and labeling of chemicals, it is unclear how nanomaterials will be identified, classified, and labeled. Nevertheless, employers must consider the potential hazards of materials they manufacture or procure. When a concern exists, the employer should utilize existing exposure control guidance or seek expertise on implementing appropriate control measures. Critical to assessing the potential health risk to the material is the need to keep updated on new and changing hazard information.

At the societal level, anticipation and identification of hazards requires government agencies and other organizations to identify what nanomaterials are being widely made and used, their hazard potential, and how to control them (OECD 2010; Safe Work Australia 2010a). This information needs to be communicated clearly and should describe the levels of certainty of the existing data and where there are gaps in the data. Government authorities and manufacturers are responsible for applying resources to test various nanomaterials, in order to better proscribe and issue hazard assessment and control guidance. Toxicological research is essential for responsible development of nanotechnology (Oberdörster et al. 2005; Oberdörster et al. 2007; Stone et al. 2013). Toxicological research first showed that nanomaterials such as ultrafine titanium dioxide (TiO2) and carbon nanotubes (CNTs) can cause adverse respiratory effects in animals, indicating the potential to cause respiratory disease in workers (Heinrich et al. 1995; Shvedova et al. 2005; Dankovic et al. 2007; Oberdörster et al. 2007). This hazard identification was not an easy task. For example, with CNTs, the challenge was not merely to expose animals to atmospheres containing CNTs, but also to consistently generate aerosols of dimensions and characteristics in animal studies that had relevance to potential worker exposures (McKinney et al. 2009).

Toxicological research is the basis for hazard identification. The responsible development of nanotechnology requires continued investment in such research. For due diligence under TSCA in the US or registration, evaluation, authorization, and restriction of chemical substances (REACH) in the European community, employers will need to continue to invest in toxicological research on nanomaterials. Linking toxicology testing to hazard determination is not new to the global chemical industry. Moving to the nanoscale has revealed new or heightened biological activity driven by size and physico-chemical properties, and employers will need to continue to explore the role of these parameters on toxicity. Better understanding of the correlation between physico-chemical properties and toxicity will facilitate assessment of hazards for new nanomaterials and the design of safer nanomaterials.

At the societal level, responsible development requires investment in toxicological assessment of widely used nanomaterials and in development of predictive models allowing estimation of hazards of new nanomaterials, as well as preventing particularly hazardous nanomaterials from entering into commerce (Oberdörster et al. 2005; Xia et al. 2010; Clark et al. 2011; Bonner et al. 2013; Winkler et al. 2012). Such efforts also need to be accompanied by communication of hazards found in such assessments. Additionally, responsible development involves anticipating future nanomaterials development and applications for commercialization. This includes consideration of more complex and active nanomaterials (Subramanian et al. 2010; Murashov et al. 2012).

Standardized characterization criteria and validated assays and algorithms are needed to classify engineered nanomaterials by the nature and degree of hazard. Given the broad diversity of nanomaterial types, this will require basic research on what properties of nanomaterials can be linked to toxic effects. Tools to make categorical estimates of toxicity, such as various alternative testing strategies, quantitative structure–activity relationship (QSAR) models, computational toxicology, and bioinformatics, need to be applied to untested materials with similar properties and used as the basis for initial risk management decisions (Kuempel et al. 2012b; Nel et al. 2013; Stone et al. 2013).

Knowledge of hazards has been increased by international collaborations such as those supported by the Organisation for Economic Co-operation and Development (OECD), United States–European union bilateral efforts, World Health Organization (WHO), International Organization for Standardization (e.g., ISO TC 229), and the various agreements between nations. Participation in these collaborations is an important aspect of responsible development.

If correct decisions are to be made about hazards, risks, and control of nanomaterials, the scientific research needs to be conducted in these areas. Whereas, results from first-generation short-term toxicity testing were used to anticipate hazards from a small number of nanomaterials and implement exposure control measures, there is ultimately a need for standardized approaches for toxicological evaluation, setting priorities for toxicity testing, and long-term (chronic health effects) investigations (Oberdörster et al. 2005; Savolainen 2012; Bonner et al. 2013; Stone et al. 2013).

It is not informative enough to just identify hazards; there also is a need to know who is being exposed to them, at what exposure concentrations, and how exposure is affected by changes in job tasks. When the degree of hazard has not been ascertained, the general guidance of government agencies is to treat candidate nanomaterials in their workplaces as if they are potential hazards until a higher level of certainty about the presence or degree of hazard is available (Philbrick 2010; Schulte et al. 2012).

Assess workers’ exposure to nanomaterials

Critical in assessing and managing risks is the measurement of exposures to nanomaterials (Ramachandran et al. 2011). This is a complex endeavor, especially this early in the natural history of engineered nanomaterials, when what constitutes appropriate exposure metrics is not clear (Brouwer et al. 2012; Ostraat et al. 2013). Nonetheless, the earliest guidance has indicated that particle mass/volume of air can be a useful metric for measuring airborne exposures to nanomaterials. Since the first issuance of the “NIOSH Approaches to Safe Nanotechnology” at the NanOEH2 symposium in Minneapolis in 2005, government guidance on how to assess worker exposure and implement risk management strategies continues to be refined and updated as new information is obtained (NIOSH 2009a).

Assessing exposures in the workplace is the employer’s responsibility, however, it is incumbent on government agencies and other organizations to assess in a general sense, the extent to which worker exposures are controlled and that guidance is provided on measurement approaches [e.g., the European Union framework 7 nanodevice project (http://www.nano-device.eu/index.php?id=123)]. The basis for this guidance, like that for identifying hazard potential, will be an evolving body of knowledge that should be continually evaluated. Continued efforts to identify hazards and determine workplace exposures are necessary to develop and update risk management guidance. Exposure is a critical factor that drives risk, and hence assessment and management of the risks. In order to minimize exposures, employers need to know and should assess what exposures actually occur, as well as their magnitude and background conditions. To adequately define occupational exposure to nanomaterials, information obtained by workplace environmental monitoring could be complemented by biological monitoring strategies that assess exposure by all routes.

Exposure assessment is important for other efforts that lead to responsible development of nanotechnology. These include helping to identify populations at risk, both in terms of actual exposures or exposure potential, and linking exposure to adverse effects in epidemiological studies (Schulte et al. 2009; Dahm et al. 2012; Riediker et al. 2012). Exposure assessment data can also serve as a sampling frame for the formation of exposure registries (i.e., lists of workers with actual or potential exposure) that can be used in future epidemiologic and health surveillance studies. Exposure assessment data are also used in conducting risk assessments and in setting occupational exposure limits (OELs) (Schulte et al. 2010). Sharing exposure data by making it publicly available would facilitate this task and should be considered a part of responsible development of nanotechnology.

Assess and communicate hazards and risks to workers

Risk assessments by definition are evaluations to predict risks when adequate data are available, although complete data are often lacking. Risk assessments are based on various assumptions and may include a high degree of uncertainty. This is especially true for nanomaterials at this early stage in their development. Yet, when adequate data are available for risk analysis, it is prudent to use such data as the basis of initial risk management decisions, while identifying and acknowledging the uncertainties.

Ultimately, the type of risk management practices needed to protect workers will depend on the extent of the risks (Schulte and Ringen 1984; Jonsen 1991; NRC 2009; Gibson et al. 2012). Risk is a probabilistic concept that depends on both the hazard and the exposure. Characterizing the reliability and the uncertainty in risk estimates will be important in risk communication and management. Employers can perform qualitative risk assessments by identifying where and to what extent exposures to nanomaterials occur, or could occur among workers in their facilities. In addition, quantitative risk assessments (QRAs) allow for estimation of risks based on empirical data. For QRAs such as those conducted by authoritative organizations, the process includes the extrapolation of toxicology data from laboratory animal studies given the limited availability of epidemiological data. For airborne nanoparticles, this involves normalization of the lung burdens associated with adverse effects in animals to estimate the equivalent human lung burdens from worker exposure information (Kuempel et al. 2006; 2012b).

Evaluating what data and information are needed to support decision-making is important in risk assessment. Although conducting QRAs on individual nanomaterials is useful, it is likely that adequate toxicological information on which to base the assessment will be available for only a small number of nanomaterials. Since there are currently many more nanomaterials than there is hazard or exposure information, it may be that risk assessment and the resulting exposure limits will focus on categories of nanomaterials (OECD 2007; Kuempel et al. 2012b). A categorical approach allowing for a relatively rapid assessment of a large number of engineered nanomaterials will be especially useful in developing risk management policies in the early decades of nanotechnology commercialization.

While hazard communication to workers is codified in laws in some countries (OSHA 2012), risk communication is less often included (HSA 2005), but is an ethical responsibility based on the right-to-know (Yale Law Journal 1981; Schulte and Ringen 1984; Jonsen 1991). The right of workers to know risk information is widely accepted and the duty of employers to communicate risk information derives from it. In some cases, explicit risk information is not available to employers, but there is information on components of risk—hazard and exposure. If employers communicate nanomaterial hazard and exposure information, they are conducting a basic form of risk communication. Hazard and risk communication related to nanomaterials are critical aspects of the responsible development of nanotechnology (CEST 2008; Schulte and Salamanca-Buentello 2007). Hazard and risk communication should be conducted by employers to nanomaterial workers, and also by manufacturers to their downstream users who may then use such information in their communications with workers.

It is not enough to merely assess risks; it is important that employers, government agencies, and other stakeholder organizations communicate what is known about the risks (Shatkin et al. 2010). Ideally, risk communication should be two-directional rather than one-directional (Ponce del Castillo 2013). The appropriate risk communication will depend on the risk perception of the intended audiences, particularly workers, and the extent to which they can participate in discussions of the risks and training about them (Kulinowski and Lippy 2012). Risk communication and risk management are most effective when workers and employers are empowered to act on those risks.

Manage occupational safety and health risks

While employers are responsible for the management of risks, they often require guidance from authorities on appropriate risk management practices. This is especially true for nanomaterials, for which the knowledge base is limited and for small employers with limited expertise or resources. The general guidance from authorities has been to be aware of where nanomaterials are used and, as a precautionary measure, to control exposures as much as reasonably achievable. Early guidance from authorities was that free, unbound nanomaterials follow the laws of classic aerosol physics and that exposures can be controlled by the same approaches historically used for fine dusts, powders, and gases. As more knowledge was accrued, guidance included benchmark, provisional, or recommended single-substance exposure limits (BSI 2007; Nakanishi 2011b; NIOSH 2011b, 2013a, b; van Broekhuizen et al. 2012). Other precautionary guidance came from applications of proposed and existing regulations to nanomaterials, such as, for manufacturers to submit risk management plans for carbon nanotubes under significant new use rules (SNUR) to the US Environmental Protection Agency (EPA) under TSCA (EPA 2013). In addition, efforts to develop voluntary consensus standards for safe handling of nanomaterials in the workplace (e.g., ISO TC 229), were an early illustration of responsible development (ISO 2009). It is the responsibility of employers to use the best available guidance as the basis for controlling exposures in the workplace (including training workers), and workers have the responsibility to cooperate with employers in carrying out risk management processes.

Various commentators have discussed the need for regulation of nanomaterials, similar to regulation of other workplace hazards (Pelley and Saner 2009; Ling et al. 2012; van Broekhuizen et al. 2012). Regulations can be critical to the implementation of good risk management practices and a keystone for responsible development of nanotechnology (Murashov et al. 2011). Although some existing general regulations may be considered to address nanomaterials, a good example of a specific approach is the recent international standard adopted in Canada for occupational exposure to engineered nanomaterials (Canadian Standards Association 2012). Voluntary international standards can be a major force in the responsible development of nanotechnology and are more likely to be in place than specific national standards as evidenced by the ISO Standards on nanotechnology (Murashov and Howard 2008; Murashov and Howard 2013). Authoritative OSH recommendations from NIOSH and other agencies or organizations provide research and health-based criteria for promoting workplace health and safety (e.g., NIOSH 2009a, 2011b, 2013a).

The general basis for managing risks from hazards, including the potential hazards of nanomaterials, is to follow the hierarchy of controls (Peterson 1973; NIOSH 2013a, b). One means of implementing the hierarchy of controls, in light of uncertainties about the hazards of nanomaterials, is by hazard and control banding approaches (Naumann et al. 1996; NIOSH 2009b; Ostiguy et al. 2010; Brouwer 2012). Some efforts in this regard are already in effect, and their continued refinement is an important aspect of responsible development of nanotechnology (Paik et al. 2008; ANSES 2010). A hazard and control banding approach can be an alternative for controlling exposures when there is insufficient information for evidence-based OELs. Additionally, an important component of the application of control banding is verification of the performance and efficacy of controls for protecting workers’ health (Jones and Nicas 2006), as well as precaution in the application of these controls when health hazard data are limited (Schulte and Salamanca-Buentello 2007).

The most effective level of the hierarchy of controls is to eliminate or design out hazards (Schulte et al. 2008b). This can be accomplished for some nanomaterials by modifying specific physico-chemical parameters of the material. The idea is that by modifying the functionality of the nanomaterials, the commercial utility of the material can be maintained while potential toxicity is reduced or mitigated. Various organizations and government agencies have been exploring this approach (http://cnse.albany.edu/Outreach/NIOSHPresentations.aspx). Responsible development of nanotechnology requires continued investment in this area.

At the societal level, responsible development of nanotechnology involves the development of national and international partnerships, and OELs. The US and the EU have supported biannual bilateral conferences on occupational safety and health issues beginning in 2009; nanotechnology was a focal topic (US–EU 2012). In 2012, a set of overarching principles to guide research, guidance, legislation, and practice were developed under this US–EU partnership (Table 3). The criteria described in this article are consistent with those principles.

Table 3.

Overarching principles to guide research, guidance, legislation, and practice involving nanotechnology

The health of workers should not be harmed by their work with nanomaterials
Globally harmonized definitions for engineered nanomaterials are needed
Transparency and traceability are essential to inform workers and employers if engineered nanomaterials are used in workplaces and where exposure may occur
Hazard and risk assessments must be performed to inform exposure control decisions for nanomaterials to which workers may be exposed
Emerging and enabling nanotechnology should apply “safe by design” principles to materials and processes to engineer out the hazardous or toxic potentials of new engineered nanomaterials as a best practice to protect workers and the environment
Early warning systems need to be developed to monitor workers’ health
Well-established industrial hygiene practices are appropriate to address nanotechnology hazards and risks
If occupational exposure limit values are not available for specific nanomaterials, a precautionary approach should be applied
Harmonized exposure assessment measurements and control strategies need to be developed for nanomaterial processes
Workers have the right to participate in developing risk management practices involving nanomaterials in the workplace

Adapted from the draft US–EU 7th joint conference on occupational safety and health, topic 1: nanotechnology at the workplace, Brussels, 11–13 July 2012. http://www.euusosh.org/

Various organizations and authorities have published OELs for nanomaterials in terms of categorical, provisional, or specific values (BSI 2007; NIOSH 2011b, 2013a, b; van Broekhuizen et al. 2012). In terms of regulatory frameworks, the promulgation of SNURs under TSCA by the EPA illustrates how employers can be required to address potential occupational safety and health concerns when using specific types of nanomaterials. Efforts to apply REACH provisions to nanomaterials are also under way. Ultimately, developing nanotechnology responsibly will require governments to work together and promote coordination and cooperation (Falkner and Jaspers 2012).

Risk management programs (e.g., evaluation of exposures, implementation of exposure controls, training, medical surveillance) for nanomaterials should be seen as part of an overall occupational safety and health program for any company or workplace producing or using nanomaterials (Schulte et al. 2008a), including those along the supply and value chains. In addition, for nanomaterials, as for many other substances in production and use, there is limited hazard information and often there are no specific OELs. Responsible development of nanomaterials also includes consideration of nanomaterials in the context of managing other workplace hazards.

An important aspect of risk management is the medical surveillance of nanotechnology workers (NIOSH 2009c). Medical surveillance allows for the identification of workers who exhibit signs and systems of adverse effects resulting from exposures to be adequately protected (Trout and Schulte 2010). For many nanomaterials, the health endpoint of interest for medical surveillance is not known, and hence only generalized medical surveillance is warranted (NIOSH 2009c). However, as new information is generated, more specific guidance for medical surveillance will be developed and should be implemented, as was recommended for workers exposed to carbon nanotubes and nanofibers (NIOSH 2013a, b).

In addition to medical surveillance, the potential long-term health experience of workers exposed to nanomaterials needs to be assessed through epidemiologic research and workplace exposure characterization studies. This is a difficult challenge since the nanomaterial workforce is widely distributed, exposed to a large number of different materials, and the appropriate health endpoints have not yet been consistently defined (Schulte et al. 2009; Riediker et al. 2012). In the short-term, cross-sectional studies using biomarkers may be the best approach; ultimately prospective and retrospective cohort studies will be needed (Li and Nel 2011; Liou et al. 2011; Schulte and Trout 2011; Riediker et al. 2012). Additionally as more hazard information becomes available, it may be useful to consider the value of registries of exposed workers in various sectors (Boutou-Kempf et al. 2011; Schulte et al. 2011). Such registries would allow more efficient identification of larger study populations, and may reduce the burden of epidemiology studies in the workplace.

Worker training is a key component in risk management and an indicator of responsible development of any technology (Kulinowski and Lippy 2012; Ponce del Castillo 2013). Although control of workplace exposures is the responsibility of the employer, training workers is integral to risk communication and management. Employers must train workers on workplace hazards and job tasks that may expose them to nanomaterials; on routes of exposure and methods used for controlling exposures; and on the use of respiratory protection and good work practices. Workers should also be informed about the potential health risks from exposure to nanomaterials and the possible need for medical surveillance (NIOSH 2009c). If nanotechnology is to be responsibly developed, worker protection has to be woven into codes of conduct, corporate responsibility pronouncements, and third-party certification schemes. Examples of such proactive efforts have illustrated how they can lead to worker protection (Nano Risk Framework 2007; Nanocyl 2009; Luigi 2009; BASF 2013; IG-DHS 2013; TÜV SÜD Industrie Service GmbH 2013; Verband der Chemischen Industrie 2012).

Continued dialog on risk management between nations and among stakeholders is needed. The international dialog on responsible research and development of nanotechnology is a firm foundation on which to build this dialog (Tomellini and Giordani 2008). Critical to the implementation of good risk management practices is the need to form partnerships among stakeholders to achieve common approaches to perceiving and controlling risks. Engaged stakeholders—such as corporations, trade associations, unions, nongovernmental organizations, insurance organizations, scientists, academic organizations, and government agencies—need to advocate for responsible development, and particularly for worker protection from potential adverse effects of nanomaterials.

Foster the safe development of nanotechnology and the realization of its societal and commercial benefits

At the societal level, responsible development of nanotechnology can provide benefits to workers and the rest of the population (Fig. 2) (Roco et al. 2011). Both the general population and the nanomaterial workforce may benefit from the diffusion of nanotechnology and nanoscience, but social and commercial benefits do not take precedence over worker safety and health. As part of the general population, workers can receive the projected societal benefits of nanotechnology (Roco 1997). These benefits may include good high paying jobs, and innovative products that address critical societal problems in materials, health, transportation, energy, and pollution. In addition to those societal gains, the workforce also benefits from nanotechnology research where nanotechnology-enabled products, such as nanotechnology-enabled sensors for detecting hazardous agents, nano-enhanced protection equipment, and nanomaterials, that are safer than traditional chemicals, have been developed to help ensure a safe work place. When workers are protected, the entire population benefits, because workers are part of it, and burdens on the population resulting from lack of protection are minimized. Others in the population are more receptive to new technologies when they see that precautions are taken, and workers are not harmed by nanomaterials (Hansen et al. 2008; Pidgeon et al. 2008; Savolainen 2012). Conversely, if the population sees that workers are harmed by nanomaterials, then it will be more resistant to products containing nanomaterials. Critical in this dynamic is the level of knowledge and certainty about protection and harm. Consequently, if employers, government agencies, or scientists are not clear in communicating the level of uncertainty about hazards and risks, or if they over-depict or under-depict those hazards and risks, then this may lead to an adverse reaction toward nanotechnology by the general population (Berube 2006; Tannert et al. 2007). If employers’ or authorities’ investments to address uncertainty are not adequate or timely, then this too can impede the development of the technology (Hansen et al. 2008; Forloni 2012). All of these aspects are components of building trust, which is critical to public engagement (Tannert et al. 2007; Berube et al. 2010).

Fig. 2.

Fig. 2

Pathways for responsible development of nanotechnology

Although avoiding hyperbole about hazards, risks, and benefits is important, it does not mean that in the face of uncertainty, immutable precautionary measures must be instituted. Rather, strict precautionary measures should be implemented when high levels of uncertainty about the potential health risk exist and then be modified as more scientific information becomes available.

If nanotechnology is to be fostered and its benefits realized, there is need to show that any health risks associated with exposure to nanomaterials can be minimized. A classic pitfall is the premise that putting one part of the population at risk can inversely provide a benefit to others (e.g., workers needlessly exposed to cotton dust in the production of cotton textile products) (American Textile Manufacturers Institute Inc. et al. versus Donovan, Secretary of Labor et al. 1981). This is contrary to the law and ethical presumptions in the United States and elsewhere. Maintaining the health and safety of the workforce while promoting development of nanotechnology can be in conflict and this must be guarded against, but since the two are linked, this linkage is promoted as an important criterion for responsible development. There cannot be responsible development of nanotechnology if workers are harmed.

The successful realization of the benefits of nanotechnology will be based, in part, on the public perception of risks and opinions of whether risk concerns are being addressed (Pidgeon et al. 2008). Although risk perception research focuses on “social risk phenomena” that are not covered in traditional risk assessment, such research needs to be an integral part of the effort in determining how the public reacts to workers’ risks and the efforts to control them (Harthorn 2006). It also should be noted that responsible development of nanotechnology involves many other factors, and ethical issues that are not derivative of worker risks (Alloff and Lin 2008).

Another aspect of responsible development of nanotechnology is the need to support research over the total life cycle of nanomaterials, so that occupational exposure to nanomaterials may not also lead to environmental exposures (Beaudrie et al. 2013). This life cycle focus may be an efficient use of resources and lead to a holistic assessment of the impact on people, organisms, and ecosystems (Karn and Bergeson 2009). Designing out the hazardous properties in nanomaterials may be a solution.

Responsible development of nanotechnology requires that society understand complex issues of hazard, exposure, dose, risk, and control as well as the potential for impact of nanotechnology on labor markets (Harthorn 2006; Pidgeon et al. 2008; Invernizzi 2011). This calls for achieving and maintaining a heightened level of scientific literacy and engagement (Bauer 2009). This will require continued and enhanced investment in education, training, and awareness across all ages and socioeconomic levels, including both workers and the general population, and it may be best to start with or include the K-12 population. The investment in education can also stimulate new generations of scientists to work on optimizing the benefits of nanotechnology.

Further, these efforts to protect workers and foster the benefits of nanotechnology must be based on a global vision, since the development, manufacture, and use of nanomaterials will be globally, albeit not evenly, distributed. Common global understanding of the elements of responsible development of nanotechnology is needed.

Extent of compliance with precautionary guidance

In these opening decades of commercial nanotechnology, there are many examples showing that the principles and practices of responsible development have enjoyed broad support (Tomellini and Giordani 2008; NNI 2011; Forloni 2012; BIAC 2013). However, it is not clear to what extent precautionary guidance is being followed. This needs to be assessed on a national and global basis. Preliminary investigations have been a good start, but reflect small response rates and potential volunteer bias (ICON 2006; Engeman et al. 2012). More detailed and rigorous evaluations are required to minimize such bias. Plans are under way to develop such evaluations, but these efforts are expensive, and it will be difficult to identify and access employers and workplaces (Schulte and Iavicoli 2012; 78 Federal Register 2013). Business, government, labor, and other organizations must invest in developing and coordinating such evaluations. Assessing the extent to which there is compliance with precautionary guidance to protect workers involved with nanomaterials is a critical benchmark of responsible development of nanotechnology. Additionally, after such an evaluation is conducted, it will be important to identify hot spots, i.e., sectors, subsectors, and types of establishments or enterprises where compliance is less than appropriate and then institute remediation and strategic intervention (such as information campaigns).

Conclusion

If the kinds of problems that have plagued previous emergent technologies are to be avoided, criteria are needed to define the responsible development of nanotechnology. The cornerstone of responsible development is the duty to protect workers, who are the first people exposed to the potential hazards of the technology. Protecting consumers and the environment are also important, but the foundation of responsible development begins with worker protection. However, these are not unrelated efforts. This article identifies five criterion actions that together can ensure responsible development of nanotechnology. All of these criteria are necessary components, and they need to be integrated with each other in practice, so that the knowledge gained through their implementation helps to advance the benefits of this technology. If these criteria are to be of value and applied, corporate and political support, globally, will be required. A lack of such support could pose a risk of harm to workers and could result in societal resistance to the development of nanotechnology.

Acknowledgments

The authors thank the following for comments on earlier drafts: Sheldon Samuels, Gregory Wagner, Knut Ringen, Ivo Iavicoli, Janet Carter, and Patricia Sullivan. The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.

References

  1. 78 Federal Register 36784 . Survey of nanomaterial risk management practices. Cincinnati: Centers for Disease Control and Prevention; 2013. [Google Scholar]
  2. Aitken RJ, Creely KS, Tran CL. Nanoparticles: an occupational hygiene review. Edinburgh: Institute of Occupational Medicine; 2004. [Google Scholar]
  3. Alloff E, Lin P, editors. Nanotechnology and society: current and emerging ethical issues. New York: Springer; 2008. [Google Scholar]
  4. American Textile Manufacturers Institute Inc. et al. versus Donovan 452 US 490 (1981) available at http://supreme.justia.com/cases/federal/us/452/490/case.html. Accessed 3 Dec 2013
  5. ANSES . Development of a specific control banding tool for nanomaterials. Córdoba: French Agency for Food, Environmental and Occupational Health and Safety. No 2008-SA-0407; 2010. [Google Scholar]
  6. Antonini JM. Health effects of welding. Crit Rev Toxicol. 2003;33(1):61–103. doi: 10.1080/713611032. [DOI] [PubMed] [Google Scholar]
  7. Ashford NA. Crisis in the workplace: occupational disease and injury. Cambridge: MIT Press; 1976. [Google Scholar]
  8. BASF (2013) Nanotechnology code of conduct. http://www.basf.com/group/corporate/en/about-basf/strategy/purpose-principles-values/code-of-conduct/index. Accessed 16 Aug 2013
  9. BAuA (Bundesanstalt für Arbeitsschutz und Arbeitsmedizin) (2007) Guidance for handling and use of nanomaterials at the workplace. http://www.baua.de/en/Topics-from-A-to-Z/Hazardous-Substances/Nanotechnology/pdf/guidance.pdf?__blob=publicationFile&v=2. Accessed 16 Aug 2013
  10. Bauer MW. The evolution of public understanding of science-discourse and comparative evidence. Sci Technol Soc. 2009;14:221–240. [Google Scholar]
  11. Bayer Material Science (2010) Occupational exposure limit (OEL) for baytubes defined by Bayer material science. http://www.baytubes.com/news_and_services/news_09116_oel.html. Accessed 16 Aug 2013
  12. Beaudrie CE, Kandlikar M, Satterfield T. From cradle-to-grave at the nanoscale: gaps in US regulatory oversight along the nanomaterial life cycle. Environ Sci Technol. 2013;47:5524–5534. doi: 10.1021/es303591x. [DOI] [PubMed] [Google Scholar]
  13. Berube DM. Nano-hype: the truth behind the nanotechnology buzz. Amherst: Prometheus Books; 2006. [Google Scholar]
  14. Berube DM, Fabee B, Scheafela DA, Cummings CL, Barduer GE, Martin MS, Temple NM (2010) Communicating risk in the 21st century: the case of nanotechnology. An independent analysis commissioned by the NNCO, Arlington. http://www.nano.gw/sites/default/files/pub_resource/berube-risk-white-paper-feb-2010.pdf. Accessed 16 Aug 2013
  15. Bonner JC, Solva RM, Taylor AJ, Brown JM, Hilderbrand SC, Castranova V, et al. Inter laboratory evaluation of rodent pulmonary response to engineered nanoparticles. Environ Health Perspect. 2013;121:676–682. doi: 10.1289/ehp.1205693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Boutou-Kempf O, Marchand J-L, Radauceanu A, Witschger O, Imbernon E, Health Risks of Nanotechnologies Group Development of a French epidemiological surveillance system of workers producing or handling engineered nanomaterials in the workplace. J Occup Environ Med. 2011;53(6):S103–S107. doi: 10.1097/JOM.0b013e31821b1d68. [DOI] [PubMed] [Google Scholar]
  17. Brouwer DH. Control banding approaches for nanomaterials. Ann Occup Hyg. 2012;56(5):506–514. doi: 10.1093/annhyg/mes039. [DOI] [PubMed] [Google Scholar]
  18. Brouwer D, Berges M, Virgi M, Fransman W, Bello D, Hodson L, Gabriel S, Tielsmans E. Harmonization of measurement strategies for exposure to manufractured nano-objects; report of a workshop. Ann Occup Hyg. 2012;56910:1–9. doi: 10.1093/annhyg/mer099. [DOI] [PubMed] [Google Scholar]
  19. Brown DM, Wilson MR, MacNee W, Stone V, Donaldson K. Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol. 2001;175(3):191–199. doi: 10.1006/taap.2001.9240. [DOI] [PubMed] [Google Scholar]
  20. BSI . Nanotechnologies, part 2: guide to safe handling and disposal of manufactured nanomaterials. London: British Standards Institution; 2007. p. 6699. [Google Scholar]
  21. Business Industrial Advisory Committee to the OECD (BIAC) (2013) Responsible development of nanotechnology turning vision into reality. http://www.biac.org/news/2013/1303_BIAC_Vision_Paper_on_Nanotechnology.htm. Accessed 26 Jul 2013
  22. CalOSHA (2013) Worker responsibilities. http://www.dir.ca.gov/dosh/workersrResponsibilities.htm. Accessed 16 Aug 2013
  23. Canadian Standards Association . Nanotechnologies—exposure control program for engineered nanomaterials in occupational settings. CSA Z-12885-12. Toronto: Canadian Standards Association; 2012. [Google Scholar]
  24. CEST (Commission de l’ Ethique de la Science et de la Technologie) Ethics, risk, and nanotechnology: responsible approaches dealing with risk. In: Allhoff F, Lin P, editors. Nanotechnology and Society. DV: Springer; 2008. pp. 75–89. [Google Scholar]
  25. Clark KA, White RH, Silbergeld EK. Predictive models for nanotoxicology: current challenges and future opportunities. Regul Toxicol Pharmacol. 2011;59:361–363. doi: 10.1016/j.yrtph.2011.02.002. [DOI] [PubMed] [Google Scholar]
  26. Colvin V (2002) Responsible nanotechnology logic: looking beyond the good news. http://www.eurekalert.org/context.php?context=nano&show=essays&essaydate=1102. Accessed 26 Jul 2013
  27. Cook WA. Maximum allowable concentrations of industrial contaminants. Ind Med. 1945;14:936–946. [Google Scholar]
  28. Dahm MM, Evans DE, Schubauer-Berigan MK, Birch ME, Fernback JE. Occupational exposure assessment in carbon nanotube and nanofiber primary and secondary manufacturers: mobile direct-reading sampling. An Occup Hyg. 2012;56(5):542–556. doi: 10.1093/annhyg/mer110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Dankovic D, Kuempel ED, Wheeler M. An approach to risk assessment for TiO2. Inhal Toxicol. 2007;19:205–212. doi: 10.1080/08958370701497754. [DOI] [PubMed] [Google Scholar]
  30. Dockery DW, Pope CA, 3rd, Xu X, Spengler JD, Ware JH, Fay ME, Ferris BG, Jr, Speizer FE. An association between air pollution and mortality in six US cities. N Engl J Med. 1993;329(24):1753–1759. doi: 10.1056/NEJM199312093292401. [DOI] [PubMed] [Google Scholar]
  31. Dressen WC, Dallavale JM, Edwards JI, Miller JW, Sayers RR. A study of asbestosis in the asbestos textile industry. Washington: US Treasury Department, Public Health Bulletin No. 241, Government Printing Office; 1938. [Google Scholar]
  32. Driscoll KE. Role of inflammation in the development of rat lung tumors in response to chronic particle exposure. Inhal Toxicol. 1996;8:139–154. [Google Scholar]
  33. Duffin R, Tran CL, Clouter A. The importance of surface area and specific reactivity in the acute pulmonary inflammatory response to particles. Ann Occup Hyg. 2002;46(Suppl 1):242–245. [Google Scholar]
  34. Eastlake A, Hodson L, Geraci CL, Crawford C. A critical evaluation of material safety data sheets (MSDS) for engineered nanomaterials. J Chem Health Safety. 2012;19(5):1–8. doi: 10.1016/j.jchas.2012.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Engeman CD, Baumgartner L, Carr BM, et al. Governance implications of nanomaterials companies inconsistent risk perceptions and safety practices. J Nanopart Res. 2012;14:749–761. [Google Scholar]
  36. EPA (2013) Significant new use rules on certain chemical substances. 40 CFR Parts 9 and 721. RIN 2070-AB27. Direct Rule. Federal Register Vol 78, Issue 152 (August 7, 2013)
  37. EU–OSHA . Workplace exposure to nanoparticles. Bilbao: European Agency for Safety and Health at Work; 2002. [Google Scholar]
  38. European Commission . Nanosciences and nanotechnologies: an action plan for Europe 2005–2009. Brussels: COM; 2005. p. 243. [Google Scholar]
  39. Falkner R, Jaspers N. Regulating nanotechnologies: risk, uncertainty and the global governance gap. Global Environ Polit. 2012;12(1):30. [Google Scholar]
  40. Forloni G. Responsible nanotechnology development. J Nanopart Res. 2012;14:1007. [Google Scholar]
  41. Gardiner K, van Tongeren M, Harrington M. Respiratory health effects from exposure to carbon black: results of the phase 2 and 3 cross sectional studies in the European carbon black manufacturing industry. Occup Environ Med. 2001;58:496–503. doi: 10.1136/oem.58.8.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Gewirth A. Human-rights and the workplace. Am J Ind Med. 1986;9(1):31–40. doi: 10.1002/ajim.4700090107. [DOI] [PubMed] [Google Scholar]
  43. Gibson R, Stacey N, Drais E, Wallin H, Zatorski W, Virpi V. Risk perception and risk communication with regard to nanomaterials in the workplace. Luxembourg: European Agency for Safety and Health at Work; 2012. [Google Scholar]
  44. Hansen SF, Maynard A, Baun A, Tickner JA. Late lessons from early warnings for nanotechnology. Nature Nanotechnol. 2008;3:444–447. doi: 10.1038/nnano.2008.198. [DOI] [PubMed] [Google Scholar]
  45. Harthorn BH. Nano-buzz: societal dimensions of emerging technologies. Anthropol News. 2006;47(7):26. [Google Scholar]
  46. Heinrich U, Fuhst R, Rittinghausen S, Creutzenberg O, Bellmann B, Koch W, Levsen K. Chronic inhalation exposure of wistar rats and 2 different strains of mice to diesel-engine exhaust, carbon-black, and titanium-dioxide. Inhal Toxicol. 1995;7(4):533–556. [Google Scholar]
  47. Hett A. Nanotechnology: small matter, many unknowns. Zurich: Zurich-Swiss Reinsurance Company; 2004. [Google Scholar]
  48. Higgins E, et al. Siliceous dust in relation to pulmonary diseases among miners in the Joplin district, Missouri. Bulletin 132. Washington: US Department of Interior, Bureau of Mines; 1917. [Google Scholar]
  49. Hinds WC. Aerosol technology. 2. New York: Wiley; 1999. [Google Scholar]
  50. Howard J. Dynamic oversight: implementation gaps and challenges. J Nanopart Res. 2011;13:1427–1434. [Google Scholar]
  51. HSA (Health and Safety Authority) Safety, health and welfare act. London: HSA; 2005. [Google Scholar]
  52. HSE . Horizons scanning information note no. HSIN1. London: Health and Safety Executive; 2004. Nanotechnology. [Google Scholar]
  53. HSE (2013) Your health, your safety: a brief guide for workers. HSE, London. http://www.hse.gov.uk/pubns/indg450.htm. Accessed 16 Aug 2013
  54. ILO (2008) Seoul Declaration on Safety and Health at Work (2008). www.seouldeclaration.org. Accessed 16 Aug 2013
  55. Interessengemieinschaft Detailhandel Schweiz (IG-DHS) (2013) Code of conduct for nanotechnologies. http://www.innovationsgesellschaft.ch/media/archive2/publikationen/CoC_Nanotechnologies_english.pdf. Accessed 17 Jan 2013
  56. International Council on Nanotechnology (ICON) A review of current practices in the nanotechnology industry. Phase two report: survey of current practices in the nanotechnology workplace. Santa Barbara: University of California Santa Barbara; 2006. [Google Scholar]
  57. Invernizzi N. Nanotechnology between the lab and the shop floor: what are the effects on labor? J Nanopart Res. 2011;13:2249–2268. [Google Scholar]
  58. IOM . Development of a biomathematical lung model to describe the exposure-dose relationship for inhaled dust among UK coal miners. In: Tran CL, editor. IOM Research Report TM/00/02. Edinburgh: B.D., Institute of Occupational Medicine; 2000. [Google Scholar]
  59. ISO . Workplace atmospheres. Ultrafine nanoparticle and nano-structured aerosols: inhalation, exposure characterization and assessment. Geneva: International Organization for Standardization, ISO/TR; 2007. p. 27628. [Google Scholar]
  60. ISO . ISO/TC 229 Nanotechnologies working group 3: health, safety and the environment, project group 6. Seattle: International Organization for Standardization; 2009. Guide to safe handling and disposal of manufactured nanomaterials, Draft report. [Google Scholar]
  61. Jacobstein N (2006) Foresight guidelines for responsible nanotechnology development. https://www.foresight.org/guidelines/ForesightGuidelinesV6.pdf. Accessed 16 Aug 2013
  62. Jones RM, Nicas M. Margins of safety provided by COSHH essentials and the ILO chemical control toolkit. Ann Occup Hyg. 2006;50(2):149–156. doi: 10.1093/annhyg/mei054. [DOI] [PubMed] [Google Scholar]
  63. Jonsen AR. Ethical considerations and responsibilities when communicating health risk information. J Clin Epidemiol. 1991;44:69–72. doi: 10.1016/0895-4356(91)90178-c. [DOI] [PubMed] [Google Scholar]
  64. Karn B, Bergeson L (2009) Green nanotechnology: straddling promise and uncertainty. American Bar Association, Natural Resource & Environment, Fall 2009, Vol. 24, Issue 2
  65. Kreider T, Halperin W. Engineered nanomaterials: learning from the past, planning for the future. J Occup Environ Med. 2011;53(6):S108–S112. doi: 10.1097/JOM.0b013e31821b146a. [DOI] [PubMed] [Google Scholar]
  66. Kuempel ED, Tran CL, Castranova V, Bailer AJ. Lung dosimetry and risk assessment of nanoparticles: evaluating and extending current models in rats and humans. Inhal Toxicol. 2006;18(10):717–724. doi: 10.1080/08958370600747887. [DOI] [PubMed] [Google Scholar]
  67. Kuempel ED, Geraci CL, Schulte PA. Risk assessment and risk management of nanomaterials in the workplace: translating research to practice. Ann Occup Hyg. 2012;56(5):491–505. doi: 10.1093/annhyg/mes040. [DOI] [PubMed] [Google Scholar]
  68. Kuempel ED, Castranova V, Geraci CL, Schulte PA. Development of risk-based nanomaterial groups for occupational exposure control. J Nanopart Res. 2012;14(9):1029. doi: 10.1007/s11051-012-1029-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Kulinowski K, Lippy B. Training workers on risks of nanotechnology. Bethesda: National Institutes of Health, National Institute of Environmental Health Sciences; 2012. p. 43. [Google Scholar]
  70. Lee JH, Kuk WK, Kwon M, Lee JH, Lee KS, Yu IJ. Evaluation of information in nanomaterial safety data sheets and development of international standards for guidance on preparation of nanomaterial safety data sheets. Nanotoxicology. 2012;7(3):338–345. doi: 10.3109/17435390.2012.658095. [DOI] [PubMed] [Google Scholar]
  71. Li N, Nel AE. Feasibility of biomarker studies for engineered nanoparticles: what can be learned from air pollution research? J Occup Environ Med. 2011;53(6):S74–S79. doi: 10.1097/JOM.0b013e31821b1bf2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Ling M-P, Lin W-C, Liu CC, Huang Y-S, Chues M-J, Shih T-S. Risk management strategy to increase the safety of workers in the nanomaterials industries. J Hazard Mater. 2012;229(230):83–93. doi: 10.1016/j.jhazmat.2012.05.073. [DOI] [PubMed] [Google Scholar]
  73. Liou S-H, Lin M-H, Hse C-H, Tsoou CJ, Li H-L, Li W-F, Lin P-P, Li L-A. The pilot study of specific biomarkers in a health effects among engineered nanoparticle. Epidemiology. 2011;22:s254–s255. [Google Scholar]
  74. Luigi F (2009) Responsible care and nanomaterials case study: Nanocyl. In: Proceedings of the European responsible care conference. http://www.cefic.org/Documents/ResponsibleCare/04_Nanocyl.pdf. Accessed 3 Dec 2013
  75. Maiello ML, Hoover MD, editors. Radioactive air sampling methods. Boca Raton: CRC Press; 2011. [Google Scholar]
  76. Maynard AD. Nanotechnology: assessing the risks. Nano Today. 2006;1(2):22–33. [Google Scholar]
  77. Maynard AD, Kuempel ED. Airborne nanostructured particles and occupational health. J Nanopart Res. 2005;7(6):587–614. [Google Scholar]
  78. McKinney W, Chen B, Frazer D. Computer controlled multi-walled carbon nanotube inhalation exposure system. Inhal Toxicol. 2009;21(12):1053–1061. doi: 10.1080/08958370802712713. [DOI] [PubMed] [Google Scholar]
  79. Merget R, Bauer T, Kupper HU, Philippou S, Bauer HD, Breitstadt R, Bruening T. Health hazards due to inhalation of amorphous silica. Arch Toxicol. 2002;75:625–634. doi: 10.1007/s002040100266. [DOI] [PubMed] [Google Scholar]
  80. Murashov V, Howard J. The US must help set international standards for nanotechnology. Nat Nanotechnol. 2008;3(11):635–636. doi: 10.1038/nnano.2008.323. [DOI] [PubMed] [Google Scholar]
  81. Murashov V, Howard J. Protecting nanotechnology workers while waiting for Godot. J Occup Environ Hyg. 2013;10(8):D116–D117. doi: 10.1080/15459624.2013.803914. [DOI] [PubMed] [Google Scholar]
  82. Murashov V, Schulte PA, Geraci C, Howard J. Regulatory approaches to worker protection in nanotechnology industry in the USA and European Union. Ind Health. 2011;49(3):280–296. doi: 10.2486/indhealth.ms1228. [DOI] [PubMed] [Google Scholar]
  83. Murashov V, Schulte PA, Howard J. Progression of occupational risk management with advances in nanomaterials. J Occup Environ Hyg. 2012;9(1):D12–D22. doi: 10.1080/15459624.2012.638217. [DOI] [PubMed] [Google Scholar]
  84. Nakanishi J (ed) (2011a) Risk assessment of manufactured nanomaterials: approaches. Overview of approaches and results. NEDO, Kawasaki City, Japan
  85. Nakanishi J (ed) (2011b) Risk assessment of manufactured nanomaterials: carbon nanotubes (CNT). NEDO, Kawasaki City, Japan
  86. Nano Risk Framework (2007) www.NanoriskFramework.com. Accessed 3 Dec 2013
  87. Nanocyl (2009) Responsible care and nanomateials case study nanocyl. Presentation at European responsible care conference, Prague 21–23rd October, 2009. http://www.cefic.be/Files/Downloads/04_Nanocyl.pdf. Accessed 23 Apr 2010
  88. Nanosafe (2008) Nanosafe2: Efficiency of fibrous filters and personal protective equipment against nanoaerosols. Paper presented at the Nanosafe 2008, 3–7 November 2008, Grenoble
  89. National Academy of Engineering (2004). Emerging technologies and ethical issues in engineering: papers from a workshop, 14–15 October 2003. National Academies Press, Washington
  90. Naumann BD, Sargent EV, Starkman BS, Fraser WJ, Becker GT, Kirk GD. Performance-based exposure control limits for pharmaceutical active ingredients. Am Ind Hyg Assoc J. 1996;57(1):33–42. doi: 10.1080/15428119691015197. [DOI] [PubMed] [Google Scholar]
  91. Nel A, Xia T, Meng H, Wang X, Lin S, Ji Z, Zhang H. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. Acc Chem Res. 2013;46:607–621. doi: 10.1021/ar300022h. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. NIOSH . Hazard review: health effects of occupational exposure to respirable crystalline silica. Cincinnati: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 2002. p. 129. [Google Scholar]
  93. NIOSH (2005) Approaches to Safe Nanotechnology: An Information Exchange with NIOSH. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Draft report for public review, Cincinnati
  94. NIOSH . Notification on precautionary measures for prevention of exposures to nanomaterials. Japan NIOSH Notification No. 0331013. Japan: Labour Standard Bureau, Ministry of Health, Labour and Welfare; 2009. [Google Scholar]
  95. NIOSH . Approaches to safe nanotechnology: managing the health and safety concerns associated with engineered nanomaterials. Cincinnati: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 2009. p. 125. [Google Scholar]
  96. NIOSH . Qualitative risk characterization and management of occupational hazards: control banding (CB): a literature review and critical analysis. Cincinnati: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 2009. p. 152. [Google Scholar]
  97. NIOSH . Current Intelligence Bulletin 60: Interim guidance for medical screening and hazard surveillance for workers potentially exposed to engineered nanoparticles. Cincinnati: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication; 2009. p. 116. [Google Scholar]
  98. NIOSH . Current intelligence bulletin 64: coal mine dust exposures and associated Health outcomes: a review of information published since 1995. Occupational exposure to titanium dioxide. Cincinnati: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 2011. [Google Scholar]
  99. NIOSH . Current intelligence bulletin 63. Occupational exposure to titanium dioxide. Cincinnati: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 2011. p. 160. [Google Scholar]
  100. NIOSH . Current intelligence bulletin 65. Occupational exposure to carbon nanotubes and nanofibers. Cincinnati: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 2013. p. 145. [Google Scholar]
  101. NIOSH . Current strategies for engineering controls in nanomaterial production and downstream handling processes. Cincinnati: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 2013. p. 102. [Google Scholar]
  102. NNI (2004) NNI strategic plan. National nanotechnology initiative, http://www.nano.gov/node/242. Accessed 3 Dec 2013
  103. NNI (2011) National nanotechnology initiative strategic plan. National nanotechnology initiative. http://www.nano.gov/node/581. Accessed 3 Dec 2013
  104. NRC . Risk assessment in the federal government: managing the process. Committee on the Institutional Means for Assessment of Risks to Public Health, Commission on Life Sciences, National Research Council. Washington: National Academies Press; 1983. [PubMed] [Google Scholar]
  105. NRC . Science and decisions: advancing risk assessment, committee on improving risk analysis approaches used by the U.S. EPA, Board on Environmental Studies and Toxicology, Division on Earth and Life Studies, National Research Council of the National Academies. Washington: National Academies Press; 2009. [Google Scholar]
  106. Oberdörster G, Yu CP. The carcinogenic potential of inhaled diesel exhaust: a particle effect. J Åerosol Sci. 1990;21(S1):S397–S401. [Google Scholar]
  107. Oberdörster G, Ferin J, Soderholm S, Gelein R, Cox C, Baggs R, Morrow PE. Increased pulmonary toxicity of inhaled ultrafine particles: due to lung overload alone? Ann Occup Hyg. 1994;38:295–302. [Google Scholar]
  108. Oberdörster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Particle Fibre Toxicol. 2005;2:8. doi: 10.1186/1743-8977-2-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Oberdörster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology. 2007;1(1):2–25. [Google Scholar]
  110. OECD . Guidance on grouping of chemicals. Series on testing and assessment, no. 80. ENV/JM/MONO(2007)28. Paris: Organization for Economic Cooperation and Development, Environmental Health and Safety Publications; 2007. [Google Scholar]
  111. OECD (2010) List of manufactured nanomaterials and list of endpoints for phase one of the sponsorship programme for the testing of manufactured nanomaterials. http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=ENV/JM/MONO(2010)46&docLanguage=En. Accessed 13 Aug 2013
  112. OSHA Hazard communication. 29CFR Parts 1910, 1915, and 19226. Fed Reg. 2012;77(58):17574–17892. [Google Scholar]
  113. OSHA . OSHA fact sheet: Working safely with nanomaterials. Washington: OSHA; 2013. [Google Scholar]
  114. Ostiguy C, Riediker M, Triolet J, Troisfontaines P, Vernez D. Expert committee (CES) on physical agents. Maisons-Alfort Cedex: French Agency for Food, Environmental, and Occupational Health and Safety; 2010. Development of a specific control banding tool for nanomaterials. [Google Scholar]
  115. Ostraat ML, Thornburg JW, Malloy GJ. Measurement strategies of airborne nanomaterials. Environ Eng Sci. 2013;30:126–132. [Google Scholar]
  116. Paik SY, Zalk DM, Swuste P. Application of a pilot control banding tool for risk level assessment and control of nanoparticle exposures. Ann Occup Hyg. 2008;52(6):419–428. doi: 10.1093/annhyg/men041. [DOI] [PubMed] [Google Scholar]
  117. Pelley J, Saner M. International approaches to the regulatory governance of nanotechnology. Ottawa: Carleton University Regulatory Governance Initiative; 2009. [Google Scholar]
  118. Peterson JE. The industrial environment—its evaluation and contro. Cincinnati: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 1973. Principles for controlling the occupational environment; p. 117. [Google Scholar]
  119. Philbrick M. An anticipatory governance approach to carbon nanotubes. Risk Anal. 2010;30(11):1708–1722. doi: 10.1111/j.1539-6924.2010.01445.x. [DOI] [PubMed] [Google Scholar]
  120. Pidgeon N, Harthorn BH, Bryant K, Rogers-Hayden T. Deliberating the risks of nanotechnologies for energy and health applications in the United States and United Kingdom. Nat Nanotech. 2008;4(2):95–98. doi: 10.1038/nnano.2008.362. [DOI] [PubMed] [Google Scholar]
  121. Ponce Del Castillo A. Nanomaterials and workplace health and safety: what are the issues for workers? Brussels: European Trade Union Institute; 2013. [Google Scholar]
  122. Pope CA, 3rd, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K, Thurston GD. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA. 2002;287(9):1132–1141. doi: 10.1001/jama.287.9.1132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Ramachandran G, Ostraat MT, Evans DE, Methner MM, O’Shaughnessy P, D’Arcy J, Geraci C, Stevenson E, Maynard A, Rickabaugh K. A strategy for assessing workplace exposure to nanomaterials. J Occup Environ Hyg. 2011;11:673–685. doi: 10.1080/15459624.2011.623223. [DOI] [PubMed] [Google Scholar]
  124. Reuzel PGJ, Bruijntjes JP, Feron VJ, Woutersen RA. Subchronic inhalation toxicity of amorphous silicas and quartz dust in rats. Food Chem Toxicol. 1991;29(5):341–354. doi: 10.1016/0278-6915(91)90205-l. [DOI] [PubMed] [Google Scholar]
  125. Riediker M, Schubauer-Berigan MK, Brouwer DH, Nelissen I, Koppen G, Frijns E, et al. A road map toward a globally harmonized approach for occupational health surveillance and epidemiology in nanomaterial workers. J Occup Environ Med. 2012;54(10):1214–1223. doi: 10.1097/JOM.0b013e31826e27f1. [DOI] [PubMed] [Google Scholar]
  126. Roco MC (1997) Introduction. WTEC Workshop report on R&D status and trends in nanoparticles, nanostructured materials, and nanodevices in the United States. World Technology Evaluation Center (WTEC), Baltimore
  127. Roco MC (2003) Societal implications of nanoscience and nanotechnology. In: Nanoscale Science Engineering and Technology (NSET) Workshop report, National Science Foundation, Arlington
  128. Roco MC, Bainbridge WS. Societal implications of nanoscience and nanotechnology: maximizing human benefit. J Nanoparticle Res. 2003;7:1–13. [Google Scholar]
  129. Roco MC, Harthorn B, Guston D, Shapria P. Innovative and responsible governance of nanotechnology for societal development. J Nanopart Res. 2011 [Google Scholar]
  130. Royal Society and Royal Academy of Engineering . Nanoscience and nanotechnologies: opportunities and uncertainties. London: Royal Society and Royal Academy of Engineering; 2004. [Google Scholar]
  131. Safe Work Australia (2010a) Work health and safety assessment tool for handling engineered nanomaterials. http://www.safeworkaustralia.gov.au/sites/swa/about/publications/pages/at201008workhealthandsafetyassessmenttool. Accessed 14 Aug 2013
  132. Safe Work Australia (2010b) An evaluation of MSDS and labels associated with the use of engineered nanomaterials. http://www.safeworkaustralia.gov.au/sites/swa/about/publications/pages/rp201006evaluationofmsdsandlabels. Accessed 14 Aug 2013
  133. Samuels SW. The environment of the workplace and human value. New York: Alan Liss Inc; 1986. [Google Scholar]
  134. Sargent EV, Kirk GD. Establishing airborne exposure control limits in the pharmaceutical industry. Am Ind Hyg Assoc J. 1988;49(6):309–313. doi: 10.1080/15298668891379792. [DOI] [PubMed] [Google Scholar]
  135. Savolainen K. Responsive development of nanotechnology. Barents Newsletter on Occupational Health and Safety. 2012;15:33–35. [Google Scholar]
  136. SCENIHR . Request for a scientific opinion on the appropriateness of existing methodologies to assess the potential risks associated with engineered and adventitious nanotechnologies. Brussels: Scientific Committee on Emerging and Newly Identified Health Risks; 2005. [Google Scholar]
  137. Schulte PA, Iavicoli I (2012) Nanotechnology. International Commission on Occupational Health (ICOH) Newsletter, Paulo Vol 10, p 8–9
  138. Schulte PA, Ringen K. Notification of workers at high risk: an emerging public health problem. Am J Public Health. 1984;74(5):485–491. doi: 10.2105/ajph.74.5.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Schulte PA, Salamanca-Buentello F. Ethical and scientific issues of nanotechnology in the workplace. Environ Health Perspect. 2007;115(1):5–12. doi: 10.1289/ehp.9456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Schulte PA, Trout DB. Nanomaterials and worker health medical surveillance, exposure registries, and epidemiologic research. J Occup Environ Med. 2011;53(6):S3–S7. doi: 10.1097/JOM.0b013e31821b1b28. [DOI] [PubMed] [Google Scholar]
  141. Schulte PA, Geraci CL, Zumwalde RD, Hoover M, Kuempel ED. Occupational risk management of engineered nanoparticles. J Occup Environ Hyg. 2008;5(4):239–249. doi: 10.1080/15459620801907840. [DOI] [PubMed] [Google Scholar]
  142. Schulte PA, Rinehart R, Okun A, Geraci CL, Heide DS. National prevention through design (PtD) initiative. J Saf Res. 2008;39(2):115–121. doi: 10.1016/j.jsr.2008.02.021. [DOI] [PubMed] [Google Scholar]
  143. Schulte PA, Schubauer-Berigan MK, Mayweather C, Geraci CL, Zumwalde RD, McKernan JL. Issues in the development of epidemiologic studies of workers exposed to engineered nanoparticles. J Occup Environ Med. 2009;51(3):323–335. doi: 10.1097/JOM.0b013e3181990c2c. [DOI] [PubMed] [Google Scholar]
  144. Schulte PA, Murashov V, Zumwalde R, Kuempel ED, Geraci CL. Occupational exposure limits for nanomaterials: state of the art. J Nanopart Res. 2010;12(6):1971–1987. [Google Scholar]
  145. Schulte PA, Mundt DJ, Nasterlack M, Mulloy KB, Mundt KA. Exposure registries: overview and utility for nanomaterial workers. J Occup Environ Med. 2011;53(6):S42–S47. doi: 10.1097/JOM.0b013e31821aebed. [DOI] [PubMed] [Google Scholar]
  146. Schulte PA, Kuempel ED, Zumwalde RD, Geraci CL, Schubauer-Berigan MK, Castranova V, et al. Focused actions to protect carbon nanotube workers. Am J Ind Med. 2012;55(5):395–411. doi: 10.1002/ajim.22028. [DOI] [PubMed] [Google Scholar]
  147. Seaton A, Tran L, Aitken R, Donaldson K. Nanoparticles, human health hazard and regulation. J R Soc Interface. 2010;7(Suppl 1):S119–S129. doi: 10.1098/rsif.2009.0252.focus. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Shatkin JA, Abbott LC, Bradley AE, Canady RA, Guidotti T, Kulinowski KM, Löfstedt R, Lonis G, MacDonell M, Maynard A, Paoli G, Shreemati L, Walker N, White R, Williams R. Nano risk analysis: advancing the science for nanomaterials risk management. Risk Anal. 2010;11:1680–1687. doi: 10.1111/j.1539-6924.2010.01493.x. [DOI] [PubMed] [Google Scholar]
  149. Shvedova AA, Kisin ER, Mercer R, Murray AR, Johnson VJ, Potapovich AI, et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol. 2005;289(5):L698–L708. doi: 10.1152/ajplung.00084.2005. [DOI] [PubMed] [Google Scholar]
  150. Stone V, Pozzi-Mucelli S, Tran L, Aschberger K, Sabella S, Vogel UB, Poland C, Balharry D, Fernandes T, Gottardo S, Hankin S, Hartl M, Hartmann N, Hristozov D, Hund-Rinke K, Johnston H, Marcomini A, Panzer O, Roncato D, Saber AT, Wallin H, Scott-Fordsmand JJ. ITS-NANO. Craig: Institute of Occupational Medicine; 2013. Research prioritisation to deliver an intelligent testing strategy for the human and environmental safety of nanomaterials. [Google Scholar]
  151. Subramanian V, Youtie J, Porter AL, Shapira P. Is there a shift to “active nanostructures’’? J Nanopart Res. 2010;12(1):1–10. doi: 10.1007/s11051-009-9729-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Tannert C, Elvers H-D, Jandrig B. The ethics of uncertainty: in the light of possible dangers, research becomes a moral duty. EMBO Rep. 2007;8(10):892–896. doi: 10.1038/sj.embor.7401072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Tomellini R, Giordani J. Third International Dialogue on Responsible Research and Development of Nanotechnology. Brussels: European Commission; 2008. [Google Scholar]
  154. Trout DB, Schulte PA. Medical surveillance, exposure registries, and epidemiologic research for workers exposed to nanomaterials. Toxicology. 2010;269(2–3):128–135. doi: 10.1016/j.tox.2009.12.006. [DOI] [PubMed] [Google Scholar]
  155. TÜV SÜD Industrie Service GmbH (2013) Nanorisk check. http://www.tuev-sued.de/technical_installations/riskmanagement/nanotechnology/nanorisk_check. Accessed 20 Aug 2013
  156. UN Conference on Environment and Development (1992) Rio declaration on environment and development, Rio de Janeiro. http://www.un.org/documents/ga/conf151/aconf15126-1annex1.htm. Accessed 16 Aug 2013
  157. US–EU Cooperation on workplace safety and health (2012) Nanotechnology in the workplace. http://useuosh.org/conference2012/nanotechnology_whitepaper.html. Accessed 13 Aug 2013
  158. van Broekhuizen P, van Broekhuizen F, Cornelissen R, Reijnders L. Workplace exposure to nanoparticles and the application of provisional nanoreference values in times of uncertain risks. J Nanopart Res. 2012;14(4):1–25. [Google Scholar]
  159. VCI (2012) Responsible production and use of nanomaterials https://www.vci.de/Services/Leitfaeden/Seiten/Responsible-Production-and-Use-of-Nanomaterials.aspx. Accessed 14 Aug 2013
  160. Winkler DA, Mombelli E, Pietroiusti A, Tran L, Worth A, Fadeel B, McCall MJ. Applying quantitative structure-activity relationship approaches to nanotoxicology: current status and future potential. Toxicology. 2012;313(1):15–23. doi: 10.1016/j.tox.2012.11.005. [DOI] [PubMed] [Google Scholar]
  161. World Health Organization (WHO) Declaration on Occupational Health for All. Geneva: World Health Organization; 1994. [Google Scholar]
  162. Xia T, Meng H, George S, Zhang H, Wang X, Ji Z, Zink JI, Nel AE. Strategy for toxicity screening of nanomaterials. Mater Matters. 2010;593:82–84. [Google Scholar]
  163. Yale Law Journal Occupational health risks and the workers’ right to know. Yale Law J. 1981;90:1792–1810. [PubMed] [Google Scholar]
  164. Zhang QW, Kusaka Y, Donaldson K. Comparative pulmonary responses caused by exposure to standard cobalt and ultrafine cobalt. J Occup Health. 2000;42(4):179–184. [Google Scholar]
  165. Zhang QW, Kusaka Y, Zhu XQ, Sato K, Mo YQ, Kluz T, et al. Comparative toxicity of standard nickel and ultrafine nickel in lung after intratracheal instillation. J Occup Health. 2003;45(1):23–30. doi: 10.1539/joh.45.23. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Nanoparticle Research are provided here courtesy of Springer

RESOURCES